Joke I Roodnat1, Luuk B Hilbrands, Ronald J Hené, Ruud G L de Sévaux, Peter J H Smak Gregoor, Judith A Kal-van Gestel, Cynthia Konijn, Arjan van Zuilen, Teun van Gelder, Andries J Hoitsma, Willem Weimar. 1. 1 Department of Internal Medicine, Erasmus Medical Centre Rotterdam, The Netherlands. 2 Department of Nephrology, Radboud University Medical Centre, Nijmegen, The Netherlands. 3 Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. 4 Dutch Transplantation Foundation, Leiden, The Netherlands. 5 Department of Nephrology University Medical Centre, Utrecht, The Netherlands. 6 Address correspondence to: J. I. Roodnat, M.D., Ph.D., Erasmus Medical Centre, Room D427, PO box 2040, 3000CA Rotterdam, The Netherlands.
Abstract
BACKGROUND:Calcineurin inhibitors (CNIs) are essential immunosuppressive drugs after renal transplantation. Because of nephrotoxicity, withdrawal has been a challenge since their introduction. METHODS: A randomized multicenter trial included 212 kidney patients transplanted between 1997 and 1999. All patients were initially treated with mycophenolate mofetil (MMF), cyclosporine A (CsA), and prednisone (pred). At 6 months after transplantation, 63 patients were randomized for MMF/pred, 76 for MMF/CsA, and 73 for MMF/CsA/pred. Within 18 months after randomization 23 patients experienced a rejection episode: MMF/pred (27.0%), MMF/CsA (6.8%) and MMF/CsA/pred (1.4%) (P<0.001). RESULTS: During 15 years of follow-up, 73 patients died with a functioning graft, and 43 patients lost their graft. Ninety-six were alive with a functioning graft. Intention-to-treat analysis did not show a significant difference in patient and graft survival. In multivariate analysis, death-censored graft survival was significantly associated with serum creatinine at 6 months after transplantation and maximum PRA but not with the randomization group. CNI withdrawal did not result in a reduced incidence of or death by malignancy or cardiovascular disease. Death-censored graft survival was significantly worse in those patients randomized for CNI withdrawal that had to be reverted to CNI. Independent of randomization group, compared with no rejection, death-censored graft survival was significantly worse in 23 patients with acute rejection after randomization. CONCLUSION: Fifteen years after conversion to a CNI free regimen, there was no benefit regarding graft and patient survival or regarding prevalence of or death by comorbidities. However, rejection shortly after CNI withdrawal was associated with decreased graft survival.
RCT Entities:
BACKGROUND: Calcineurin inhibitors (CNIs) are essential immunosuppressive drugs after renal transplantation. Because of nephrotoxicity, withdrawal has been a challenge since their introduction. METHODS: A randomized multicenter trial included 212 kidneypatients transplanted between 1997 and 1999. All patients were initially treated with mycophenolate mofetil (MMF), cyclosporine A (CsA), and prednisone (pred). At 6 months after transplantation, 63 patients were randomized for MMF/pred, 76 for MMF/CsA, and 73 for MMF/CsA/pred. Within 18 months after randomization 23 patients experienced a rejection episode: MMF/pred (27.0%), MMF/CsA (6.8%) and MMF/CsA/pred (1.4%) (P<0.001). RESULTS: During 15 years of follow-up, 73 patients died with a functioning graft, and 43 patients lost their graft. Ninety-six were alive with a functioning graft. Intention-to-treat analysis did not show a significant difference in patient and graft survival. In multivariate analysis, death-censored graft survival was significantly associated with serum creatinine at 6 months after transplantation and maximum PRA but not with the randomization group. CNI withdrawal did not result in a reduced incidence of or death by malignancy or cardiovascular disease. Death-censored graft survival was significantly worse in those patients randomized for CNI withdrawal that had to be reverted to CNI. Independent of randomization group, compared with no rejection, death-censored graft survival was significantly worse in 23 patients with acute rejection after randomization. CONCLUSION: Fifteen years after conversion to a CNI free regimen, there was no benefit regarding graft and patient survival or regarding prevalence of or death by comorbidities. However, rejection shortly after CNI withdrawal was associated with decreased graft survival.
Authors: Chen-Fang Lee; Ying-Chun Lo; Chih-Hsien Cheng; Georg J Furtmüller; Byoungchol Oh; Vinicius Andrade-Oliveira; Ajit G Thomas; Caitlyn E Bowman; Barbara S Slusher; Michael J Wolfgang; Gerald Brandacher; Jonathan D Powell Journal: Cell Rep Date: 2015-10-17 Impact factor: 9.423
Authors: Donald E Hricik; Richard N Formica; Peter Nickerson; David Rush; Robert L Fairchild; Emilio D Poggio; Ian W Gibson; Chris Wiebe; Kathryn Tinckam; Suphamai Bunnapradist; Milagros Samaniego-Picota; Daniel C Brennan; Bernd Schröppel; Osama Gaber; Brian Armstrong; David Ikle; Helena Diop; Nancy D Bridges; Peter S Heeger Journal: J Am Soc Nephrol Date: 2015-04-29 Impact factor: 10.121
Authors: J Jansen; M Fedecostante; M J Wilmer; J G Peters; U M Kreuser; P H van den Broek; R A Mensink; T J Boltje; D Stamatialis; J F Wetzels; L P van den Heuvel; J G Hoenderop; R Masereeuw Journal: Sci Rep Date: 2016-05-31 Impact factor: 4.379
Authors: Marieke van der Zwan; Marian C Clahsen-Van Groningen; Joke I Roodnat; Anne P Bouvy; Casper L Slachmuylders; Willem Weimar; Carla C Baan; Dennis A Hesselink; Marcia M L Kho Journal: Ann Transplant Date: 2018-08-17 Impact factor: 1.530